OBJECTIVE-Both the early steps and the high recurrence of autoimmunity once the disease is established are unexplained in human type 1 diabetes. Because CD8 + T cells are central and insulin is a key autoantigen in the disease process, our objective was to characterize HLA class I-restricted autoreactive CD8 + T cells specific for preproinsulin (PPI) in recent-onset and long-standing type 1 diabetic patients and healthy control subjects.
RESEARCH DESIGN AND METHODS-We used HLA-A*02:01 tetramers complexed to PPI peptides to enumerate circulating PPIspecific CD8 + T cells in patients and characterize them using membrane markers and single-cell PCR.
RESULTS-Most autoreactive CD8
+ T cells detected in recentonset type 1 diabetic patients are specific for leader sequence peptides, notably PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] , whereas CD8 + T cells in long-standing patients recognize the B-chain peptide PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (B 9-18 ). Both CD8 + T-cell specificities are predominantly naïve, central, and effector memory cells, and their gene expression profile differs from cytomegalovirus-specific CD8 + T cells. PPI 6-14 -specific CD8 + T cells detected in one healthy control displayed Il-10 mRNA expression, which was not observed in diabetic patients.
CONCLUSIONS-PPI-specific CD8 + T cells in type 1 diabetic patients include central memory and target different epitopes in new-onset versus long-standing disease. Our data support the hypothesis that insulin therapy may contribute to the expansion of autoreactive CD8 + T cells in the long term. Diabetes 60:3289-3299, 2011 T ype 1 diabetes is an autoimmune disease driven by the activation of lymphocytes against pancreatic b-cells. Although the successive steps that control the activation of autoreactive lymphocytes have been extensively studied in animal models, the disease process remains ill defined in human type 1 diabetes (1) . In mice, type 1 diabetes is transferred into naïve recipients by T cells, is prevented by antibodies that target T-cell differentiation, and fails to develop when key genes in T-cell differentiation or activation are nonfunctional. In humans, T cells-especially CD8 + T cells-are predominant within insulitis in most observations (2) (3) (4) (5) . Occurrence of type 1 diabetes in a patient deprived of B lymphocytes further underscores the role of T cells (6) . An unexpected feature is the high recurrence level of autoimmunity in long-standing type 1 diabetic patients. Rapid diabetes recurrence is seen in type 1 diabetic recipients of isograft from a nondiabetic twin, accompanied by an almost exclusive islet CD8 + T cell infiltration (7). b-Cell-specific T cells thus seem to maintain immune memory for years after type 1 diabetes onset. However, the differentiation patterns of autoreactive T cells once diabetes is diagnosed remain largely unknown.
Insulin has been ascribed a key antigenic role in type 1 diabetes. Altered diabetes development in proinsulin 1 2/2 or 2 2/2 NOD mice makes a strong case for the primary role of insulin in the NOD mouse (8) (9) (10) . In humans, insulin and proinsulin are common targets of autoantibodies and T cells in prediabetic and diabetic individuals. Insulin autoantibodies are the first to be detected in children at risk for type 1 diabetes and carry a high positive predictive value for diabetes in siblings of patients (11) . A restricted region of proinsulin located in the B chain and adjacent C-peptide clusters has epitopes that are recognized by CD8 + T cells (12) (13) (14) (15) (16) . Other epitopes are located within the A chain, the C-peptide and C-peptide-B chain junction (14) , and preproinsulin (PPI) leader sequence (13, 17, 18) , including residues excised during insulin processing. PPI-reactive CD8 + T cells have mostly been observed in recent-onset type 1 diabetic patients (12, 13) . However, some peptides, in particular peptides located in the insulin B chain, allow the detection of interferon-g (IFN-g)-producing CD8 + T cells in long-standing patients who have been treated with insulin for decades (12) .
Most studies have used IFN-g enzyme-linked immunospot (ELISpot) assays to characterize autoreactive CD8 + T cells (12) (13) (14) (15) . More recently, HLA class I tetramers (TMrs) have identified CD8
+ T cells expressing a T-cell receptor specific for HLA class I-restricted peptides, independently of cytokine production (13, 18, 19) . Developing T-cell assays is a major challenge in human type 1 diabetes. It is therefore expected to help in identifying epitopes recognized by T cells and to pave the way toward immunotherapy to restore tolerance to b-cells. New T-cell technologies are expected to allow defining autoreactive T-cell differentiation programs and characterizing autoimmune responses in comparison with physiologically appropriate immune responses.
Here, we used TMrs to detect insulin-reactive CD8 + T cells in type 1 diabetic patients and characterize their functional profile in comparison with cytomegalovirus (CMV)-specific CD8 + T cells. Remarkably, CD8 + T cells detected in recent-onset type 1 diabetic patients are specific for leader sequence peptides, especially PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] . The detection of CD8 + T cells against an insulin B-chain peptide in patients with established disease raises the hypothesis that insulin therapy may also contribute to expansion of autoreactive CD8 + T cells.
RESEARCH DESIGN AND METHODS
Patients. Type 1 diabetic patients (n = 49) were HLA-A*0201 + and positive for anti-GAD, anti-insulin, or anti-IA2 autoantibodies at diagnosis (Table 1) . Recentonset patients (14 males, 11 females; aged 38.1 6 11.1 years) were studied within 3 months from diagnosis (median 3 days; range 2-70 days). Long-standing type 1 diabetic patients (13 males, 11 females; aged 41.4 6 11.6 years) had a median type 1 diabetes duration of 4 years (range 2-40). Control subjects were healthy blood donors (12 males, 9 females; aged 35.6 6 11.8 years), type 2 diabetic patients under oral treatment (3 males, 4 females; mean age 56.6 6 9.0 years) or insulin treatment (3 males, 4 females; mean age 55.4 6 7.7 years) selected as expressing HLA-A*0201. Informed consent was obtained and the study was approved by the local ethics committees. HLA class I alleles were determined by Ambisolv genotyping (Dynal/Invitrogen) on DNA with Gentra Puregene Blood kit A (Qiagen). C-peptide was measured by time-resolved fluoroimmunoassay using Wallac Delfia reagents (Perkin-Elmer SAS, Courtaboeuf, France). Lower detection limit was 3.3 pmol/L. The intra-and interassay coefficients of variation at the level 1.1 ng/mL (364 pmol/L) were 3.9 and 5.2%, respectively, and at the level 6 ng/mL (1986 pmol/L) 3.1 and 3.4%, respectively. Intact insulin did not cross-react with C-peptide in this assay. TMrs. PPI peptides were selected from PPI sequence, synthetized, and purified as previously described (20) ( Table 2 ) and were controlled by MALDI-TOF (matrix-assisted laser desorption/ionization2top of flight) on a Bruker Protein TOF mass spectrometer (12) . Peptide nomenclature refers to N and C termini along the PPI protein sequence. Peptide binding to HLA-A*0201 was determined by major histocompatibility complex stabilization assays using TAP2-deficient HLA-A*0201-transfected T2 cells (21, 22) . Percent mean fluorescence intensity (MFI) increase corresponds to (MFI with a given peptide -MFI without peptide)/ (MFI without peptide). For TMr assembly, HLA-A*0201 a-chain and human b2-microglobulin were produced in E. coli. HLA-A*0201/peptide monomers were refolded in vitro using 12 mg of peptide, purified by gel filtration (Superdex 200HR 10/30, Pharmacia), and biotinylated using the biotin-protein ligase BirA (Avidity) (23) . Purified biotinylated HLA-A*0201/peptide monomers were tretramerized with Extravidin-R-Phycoerythrin conjugate (Sigma) (21, 24) . TMr assays. Peripheral blood mononuclear cells (PBMCs) were prepared from fresh blood using Lymphoprep (Axis Shield) separation in Leucosep tubes. TMr staining was performed by incubating 10 6 PBMCs with 5-10 mg/mL phycoerythrin (PE)-labeled TMrs at 37°C for 30 min. Anti-CD45RA-FITC, anti-CCR7-PE-Cy7, anti-CD8-PerCP (SK1 clone), and anti-CD3-APC-Cy7 antibodies (BD Pharmingen, eBioscience) were then added for 15 min at 4°C. After washing, cells were acquired on a BD FACSAria and analyzed using FlowJo (Tree Star) (25, 26 + T cells were sorted on a FACSAria at 1 cell/well into 96-well PCR plates containing 5 ml PBS treated with diethyl pyrocarbonate (Sigma) and immediately frozen at 280°C. Single-cell reverse transcriptase PCR. RNA was extracted from sorted cells by direct cellular lysis for 2 min at 65°C. Procedures and primers for coamplification of multiple genes in single cells were designed as described (27, 28) . Reverse transcription was carried out with murine leukemia virus reverse transcriptase (Applied Biosystems) for 60 min at 37°C. Seminested PCR was then performed with gene-specific primers (Eurogentec) and AmpliTAQ Gold Polymerase (Applied Biosystems) by touch-down PCR. PCR products were resolved on a 2.5% (w/v) agarose gel. Perforin (Prf1), granzyme A (Gzma), granzyme B (Gzmb), Fas ligand (Fasl), IFN-g (Ifng), TGF-b1 (Tgfb1), TNF-a (Tnfa), IL-2 (Il2), IL-10 (Il10), IL-10Ra (Il10ra), IL-7R (Il7r), MIP-1a (Mip1a), MIP-1b (Mip1b), PD1 (Pd1), RANTES (Ccl5), KLRG1 (Klrg1), CCR7 (Ccr7), and CD3´(Cd3e) mRNAs were analyzed. Statistical methods. Comparison of distribution scores between patients and control subjects and TMr assessment used the nonparametric Kruskal-Wallis test or Fisher exact test. To study assay reliability, we used the graphical Altman and Bland method, which focuses on means and variability of differences between repeated measurement pairs (29) . C-peptide levels were compared using the Mann-Whitney U test.
RESULTS

Insulin-specific CD8
+ T cells are detected in type 1 diabetic patients. PPI peptides are recognized by CD8 + T cells from type 1 diabetic patients using IFN-g ELISpot (12-15), which, methodologically, restricts recognition to (Fig. 1F ) or in absence of TMrs (Fig. 1G) . As expected, more cells were often stained with HLA-A2/CMV TMrs than with A2/PPI TMrs (Fig. 1H ).
Significant differences were observed among recent-onset, long-standing type 1 diabetic patients, and control subjects in the frequencies of TMr + CD8 + T cells specific for PPI leader sequence peptides PPI 6-14 , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and B-chain peptide PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (B 9-18; Fig. 2A) . Percentages of CD8 + T cells specific for leader sequence peptide PPI 2-11 , B chain peptides PPI [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , PPI [34] [35] [36] [37] [38] [39] [40] [41] [42] , and PPI [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] , and A chain peptide PPI 101-109 did not differ significantly among groups, but few individual responses were seen against these peptides ( Fig. 2A and Supplementary Table 1 ). There was no significant difference in PPI-specific CD8 + T cells between healthy controls and type 2 diabetic patients, including with insulintreated Type 2 diabetic patients (data not shown), and in CMV-specific CD8 + T cells between type 1 diabetic patients and control subjects ( Fig. 2A) . The number of individuals whose TMr + frequencies were $95th percentile of control subjects was different between recent-onset patients and control subjects for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] TMr + cells (8/25, 32.0%; P , 0.03) and PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (8/25, 32.0%; P , 0.03) but not for PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (7/25, 28.0%; P = 0.06) and between long-standing type 1 diabetic patients and control subjects for PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (12/24, 50.0%; P , 0.002) but not for PPI 6-14 (9/24, 37.5%; P = 0.35) and PPI 15-24 (7/24, 29.2%; P = 0.055). In a healthy control subject, a high (0.14%) frequency of PPI 6-14 -specific CD8 + T cells was observed ( Fig. 2A) .
Assay reliability was calculated from values obtained from two assays performed in two different samples collected at median intervals of 3 days following diagnosis (range 2-90 days) in the same individuals using PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , and CMV pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] TMrs. Differences of up to 60.038, 0.042, 0.060, and 0.186% were observed for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , and CMV pp65 495-503 TMrs, respectively. Mean differences represent interassay mean errors and intervals acceptable errors. There is good interassay agreement for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] peptides, each value being included in the error interval, which is #0.05 (Fig. 2B) . Overall, 68% of recent-onset and 83.3% of long-standing type 1 diabetic patients had detectable PPI-specific CD8 + T cells above the 95th centile of control subjects. Responses were observed against at least two peptides in 44.9% of patients (22/49), including 32.6% (16/49) who showed a response to either PPI 6-14 , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] .
In long-standing patients who stained positive for A2/PPI TMrs, mean diabetes duration was 6.5 years (range: 3-25) for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] peptide, 14.4 years (3-39) for PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] peptide, and 10.7 (3-39) for PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] peptide. Basal C-peptide values were available in 11/19 patients in whom increased A2/ PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] TMr + CD8 + T cells (TMr + patients) were detected and 7/30 patients in whom A2/PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] TMr + CD8 + T cells were in the basal range (TMr 2 patients). Although differences between both groups were not significant, lower C-peptide values were observed in TMr + patients (median 0.07 6 0.09 nmol/L; range 0.01-0.27) than in TMr 2 ones (median 0.22 6 0.19 nmol/L; range 0.01-0.59; P = 0.07) (Fig.  3A) . Moreover, an inverse correlation was observed between percentages of A2/PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] TMr + CD8 + T cells detected and fasting C-peptide values (r = 20.63; P = 0.05) (Fig. 3B) . (Fig. 4A and B ). Significant differences were seen in the distribution of CMV-specific and PPI-specific CD8 + naïve and memory T cells between type 1 diabetic patients and control subjects using the Kruskal-Wallis test, but not between recent-onset and long-standing type 1 diabetic patients (Fig. 4C) . In recentonset and long-standing type 1 diabetic patients, 31.5 and 32.0% TN PPI-specific CD8 + cells were detected, respectively, whereas these cells were almost undetectable among CMV-specific T cells. Similarly, PPI-specific TCMs represented 25.4 and 29.8% of CD8 + T cells in the two respective type 1 diabetic populations, whereas they represented only 15.6% of CMV-specific CD8 + T cells (P = 0.0071).
FIG. 2. Distribution of CD8+
T cells specific for A2.1-restricted PPI peptides in type 1 diabetic patients and control subjects. A: Each symbol represents the percentage of CD8 + T cells specific for A2.1-restricted PPI and control peptides detected in individual recent-onset type 1 diabetic (•), long-standing type 1 diabetic (■), and healthy and type 2 diabetic control (▲) subjects. A significantly higher percentage of CD8 + T cells specific for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] (P = 0.0123), PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (P = 0.0369), and PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (P = 0.001) was observed in recent and long-standing type 1 diabetic patients compared with control subjects (Kruskal-Wallis test). Differences in detection of A2/PPI TMr + were significant for leader sequence [6] [7] [8] [9] [10] [11] [12] [13] [14] , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] TMrs (mean difference 6 SD: 0.000 6 0.019, 0.001 6 0.021, and 0.005 6 0.028, respectively) and 0.000-0.008 for CMV pp65 495-503 TMrs (0.008 6 0.09). The scatter plot of the difference between the measurements against their mean allows detecting no lack of individual reliability, which may be hidden by the use of global reliability statistics for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , and CMV pp65 495-503 TMr levels (24) .
In contrast, PPI-specific TEM and TEMRA were underrepresented in recent-onset (8.19%) and long-standing (12.1%) patients, as compared with CMV-specific TEM and TEMRA CD8 + T cells (50.47 and 29.97%, respectively). There was no difference in distributions of PPI 6-14 -, PPI 15 (Fig. 5) . Gene expression in PPIspecific (Fig. 5A ) and CMV-specific (Fig. 5B) CD8 + T cells was different. Figure 5A illustrates a representative subject (R18) displaying 0.19% A2/PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] TMr + CD8 + T cells of which only 4.3% coexpressed Pfr and Gzma or Gzmb, none coexpressed Ccl5 (coding for RANTES) and Mip1b, but 40% expressed Ccr7. Opposite profiles were seen in A2/CMVspecific CD8 + T cells. In patient L9 (Fig. 5B ), 2.0% A2/CMV TMr + CD8 + T cells were detected of which 36% coexpressed Pfr and Gzma or Gzmb but only 4% expressed Ccr7, while 32% coexpressed Ccl5 and Mip1b.
Gene expressions were strikingly comparable in A2/ PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] , PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] TMr + CD8 + T cells (data not shown). Considering the whole type 1 diabetic population, the mean percentage of PPI-specific CD8 + T cells that expressed Pfr and Gzma and Gzmb was 16.1, 11.0, and 6.9%, respectively, as compared with 51.5, 40.7, and 21.4% for CMV-specific CD8 + T cells (P = 0.0003, P = 0.0092, P = 0.0125, respectively; Fig. 5D ). Differences in chemokine gene expression were also seen, such as Ccl5 and Mip1b, which drive immune cells to inflammatory sites. Indeed, a higher number of CMV-specific CD8 + T cells expressed Ccl5 compared with PPI-specific CD8 + T cells (81.9 vs. 27.8%; P=0.0026), and the same result was observed for Mip1b (20.6 vs. 6.0%; P = 0.01). By contrast, Ccr7, which controls recirculation through lymph nodes, was more expressed by PPI-specific CD8 + T cells (30.9%) than CMVspecific CD8 + cells (3.4%; P , 0.001). These data suggest that PPI-specific CD8 + T cells display gene expression programs that largely overlap TCM rather than TN phenotypes, based on expression of IFN-g and Rantes genes (33), whereas CMV-specific CD8 + T cells are predominantly TEM cells. Expression of Fasl, Tnfa, Il2, Mip1a, and Il10 genes was remarkably rare. Expression of the Il7ra gene was above 70% in both A2/CMV and A2/PPI peptide TMr + CD8 + T cells. In contrast with previous reports (34), the expression of Klrg1 by CMV-specific CD8 + T cells was heterogeneous, whereas it was low in most PPI-specific CD8 + T cells. A significant difference was further observed in expression of Pd1 between PPI-and CMV-specific CD8 + T cells (3.0 vs. 11.1%; P = 0.0117). There was no significant difference in gene expression levels by PPI-specific CD8 + T cells between recent-onset and long-standing type 1 diabetic patients (data not shown). In the only control individual who showed detectable PPI 6-14 -specific CD8 + T cells ( Fig. 2A) , a unique gene expression program was observed, with 34% CD8 + T cells expressing Il10, as compared with 2.2 6 3.3% of PPI 6-14 -specific CD8 + T cells in type 1 diabetic patients. PPI-specific CD8 + T cells in type 1 diabetes using IFN-g ELISpot (12), we here report the presence of circulating PPI-specific CD8 + T cells in type 1 diabetes. PPI-specific CD8 + T cells were detected against three major peptides, two within the PPI leader sequence (PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] and PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and one within the insulin B chain (PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] ; also known as B [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ). CD8 + T cells that were specific for other PPI peptides were only seen in few patients. Overall, CD8 + T cells specific for at least one PPI peptide were detected in 68% of recent-onset and 83% of long-standing type 1 diabetic patients. These figures are likely underestimated, since stable TMrs were only obtained with peptides that showed sufficient binding affinity to HLA-A*0201 (Table 2) . However, we cannot rule out that PPI-specific T cells not tested here are activated in type 1 diabetes and that different peptides are recognized at different stages of type 1 diabetes because we only tested individuals with clinical diabetes.
HLA-A*0201-restricted leader sequence peptides are commonly presented to CD8 + T cells, as previously reported for PPI [6] [7] [8] [9] [10] [11] [12] [13] [14] and PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (12, 15) . PPI 6-14 -and PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] specific CD8 + T cells have previously been shown to be cytotoxic against human islet T cells and HLA-A*0201-transfected P815 target cells, respectively (13, 17) . Recognition of PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] has been reported to increase when human islets were incubated in the presence of high glucose concentrations (17) , adding further insight into its role in the natural history of human type 1 diabetes.
The differentiation of memory T cells in relation to antigen exposure has been extensively studied in immune responses to viruses but remains poorly understood in autoimmunity. Clinical diabetes occurs after a preclinical phase that spans over years in many patients. However, the b-cell mass in prediabetes and the level of autoantigen exposure once diabetes is diagnosed remain unknown (35, 36) . The persistence of CMV infection with time makes it a relevant control, since T cells are kept exposed to low levels of CMV antigens, as is the case for autoimmune T cells exposed to residual b-cells (36) . We limited our study of membrane markers of PPI-specific CD8 + T cells to CCR7 and CD45RA, which discriminate central memory from effector memory CD8 + T cells. However, CD45RA does not fully correlate with effector memory functions. Markers such as CD27 and CD28 further discriminate at least three and four different CD8 + subsets within CCR7 2 CD45RA 2 and CCR7
2
CD45RA
+ CMV-specific cells, respectively (25) . These markers were, however, less relevant to study PPI-specific CD8 + T cells as these cells were mostly within the CD45RA 2 CCR7 + central memory compartment. CD45RA + CD45RO
+ double-positive T cells have been identified as possibly representing a transition population from naïve CD45RA + to memory CD45RO + T cells. This population has been shown to be increased in recent-onset type 1 diabetic patients but not in long-standing patients, possibly reflecting an imbalance between the two CD45 isoforms in autoimmunity (37). Because we did not exclude CD45RA + CD45RO + T cells from the analysis of memory cells, we cannot exclude that we lost these transition cells that are likely to be included in naïve cells in our analysis. However, we saw the same increase in memory PPI-specific CD8 + T cells in long-standing type 1 diabetic patients in whom the double-positive CD45RA + CD45RO + T cell is not increased. A recent work has reported the predominant detection of TN and TEMRA CD8 + T cells, but they were specific for different peptides, i.e., PPI 2-10 and PPI [34] [35] [36] [37] [38] [39] [40] [41] [42] , with higher percentages of detection and in subjects who had possibly been treated with anti-CD3 antibody (38) .
Analysis of postactivation CD8
+ T cells actually illustrates much greater diversity in survival, recall potentials as well as tissue specificity than is defined by current phenotypic markers (32 [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] are remarkable because exposition to B chain epitopes persists in insulintreated, long-standing, type 1 diabetic patients independently of the persistence of residual b-cells. However, this may not be an exclusive mechanism, since PPI 15-24 -specific CD8 + T cells were detected in a subset of patients with longstanding diabetes, and thus independently of insulin therapy because insulin preparations are devoid of PPI leader sequence. No correlation was observed between detection of PPI 15-24 -specific CD8 + T cells and type 1 diabetes duration. Of further note, a significant fraction of PPI-specific T cells displayed a naïve status that was virtually absent in the CMV-specific repertoire, suggesting that there is still an unexpressed potential for further autoimmune activation in most patients. This unexpressed potential may explain the arousal of PPI 33-42 -specific CD8 + T cells upon insulin treatment in long-standing patients. Indeed, these cells were not detected in type 2 diabetic patients treated with insulin, suggesting that insulin treatment may effectively expand them only in the presence of preexisting autoimmunity. The detection of naïve PPI-specific CD8 + T cells may indicate their preexistence and maintenance in the repertoire of type 1 diabetic patients in relation with the slow chronic process that characterizes type 1 diabetes. Adding further value to the extensive functional characterization carried out by single-cell PCR, one single healthy subject harbored PPI 6-14 -specific CD8 + T cells expressing the regulatory cytokine Il10. Thus, the mere presence of autoreactive CD8 + T cells may not be considered pathogenic, as previously suggested for islet-reactive CD4 + T cells (39) . We observed a differentiated CMV-specific CD8 + T cell phenotype, as previously reported (25) , with low expression of Ccr7 and high expression of cytolytic effector molecules and significant diversity among individuals. By contrast, PPI-specific CD8 + T cells expressed higher levels of Ccr7-presumably allowing them to repeatedly circulate to lymph nodes rather than directly homing to the islets-and lower levels of cytolytic effector molecules. An important factor in driving distinct memory T-cell phenotypes is the strength of T-cell activation in relationship with local factors in secondary lymphoid organs in which the initial T-cell activation takes place and at the inflammatory site (32, 40) . Expression of homing receptors for lymph nodes have usually been associated with situations in which low strength of activation or a low antigen load is seen (41) . Although in most instances antigen persistence is not required for maintenance of memory T cells, recent data in type 1 diabetes suggest that long-standing type 1 diabetic patients may still harbor residual b-cells (42, 43) .
The detection of B chain-specific CD8 + T cells in a significant fraction of long-standing type 1 diabetic patients indicates that memory CD8 + T cells persist in the long-term range despite the likelihood that autoimmunity to b-cells is progressively downregulated, since residual b-cells disappear. This persistence of detectable central memory CD8 + T cells in the long term raises several nonexclusive hypotheses. They may persist in the absence of residual b-cells or in the presence of a minimal residual b-cell mass, either resisting autoimmune destruction or regenerating as destruction proceeds, as proposed in the NOD model (44) . The persistent detection of PPI 6-14 -and, to a larger extent, PPI 15-24 -specific CD8 + T cells in few long-standing patients is compatible with either hypothesis. Alternatively, long-term treatment with exogenous insulin may contribute to activation of T cells against B-chain peptides. This is relevant in the light of the clinical observation that type 1 diabetes is a highly recurrent disease in patients who have been treated with exogenous insulin for years. The negative correlation observed between the percentage of A2/PPI [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] TMr + CD8 + T cells detected in type 1 diabetic patients and residual basal C-peptide values is compatible with this hypothesis.
In conclusion, a majority of type 1 diabetic patients harbor PPI-specific CD8 + central memory T cells. The absence of these cells in most control individuals makes a strong case for the role of PPI-specific CD8 + T cells in type 1 diabetes. Although type 1 diabetes is characterized by active autoimmunity many years after disease onset, our observation that exogenous insulin may contribute to expansion of autoreactive CD8 + T cells in the long term brings a new light to the natural history of the disease.
